Zhenyi Medical Establishes Xiamen Subsidiary to Accelerate Innovation and Commercialization in Structural Heart Disease

In September 2025, Jiangsu Trulive Medtech Co., Ltd. ("Trulive"), in which C&D Emerging Investment and its partner Ji Feng Capital jointly invested, established a research and innovation center as well as a professional education and marketing center in Xiamen, accelerating the R&D and commercialization process of innovative products for structural heart disease.

Trulive, established in 2019, is a specialized cardiovascular interventional medical device platform enterprise focused on solving blood flow direction issues. The company has developed a one-stop toolbox for cardiovascular treatment, offering solutions for various blood flow direction problems, including valve management — the treatment of heart valve disease to ensure proper blood flow direction; clearance — the treatment of vascular stenosis or occlusion to ensure smooth blood flow; and shunting — the intervention for heart failure to relieve pathological high pressure.

C&D Emerging Investment consistently upholds the philosophy of "investing early, investing small, investing long-term, and investing in hard technology." As early as 2021, it participated in Trulive's Series A financing round and completed two follow-up investments in 2022 and 2023. When C&D Emerging Investment first invested in Trulive, the company had fewer than 30 employees, and all products were still in the early stages of research and development, not yet undergoing human trials. After four years of support and continued investment, Trulive has made rapid progress in product development, quickly emerging as a "dark horse" in the cardiovascular interventional treatment field, achieving significant results. Currently, the company has obtained Class III national medical device registration certificates for three core products, with multiple other products in the clinical trial stage, leading in progress within China. In the coming years, Trulive is set to enter a commercial harvest period. The establishment of this Xiamen subsidiary will allow Trulive to directly benefit from Xiamen’s industry and clinical resources, promoting faster and better development through physician-engineering collaboration, professional education, and commercial promotion.

Wen Jing, Chairman of Trulive, stated: The development of Trulive is inseparable from the support of Xiamen. Since 2021, it has received multiple rounds of investment from C&D Emerging Investment. Last year, it gained the support of Xiamen Torch High-Tech Investment, and this year it received a new round of support from Xiamen Cardiovascular Industry Fund and Xiamen Industrial Investment. Ultimately, with the promotion of all shareholders in Xiamen, Trulive successfully established its long-planned research, education, and marketing center in Xiamen. This not only marks a historic upgrade in Trulive's industrial R&D system but also serves as a key engine for the company’s overall strategy of "rooted in China, facing the globe." This collaboration will provide a new opportunity for Trulive to further implement professional education, expand market space, and deepen industrial layout. The project benefits from Xiamen's excellent business environment and biomedicine industry foundation. In the future, the company will further leverage Xiamen's industrial and geographical advantages, continue to deepen medical-engineering cooperation, promote the deep integration of clinical practice and scientific research innovation, accelerate technological breakthroughs and achievement transformation, and contribute to the rapid development of Xiamen's high-end medical device innovation field.

As a wholly-owned subsidiary of Xiamen C&D Group, a state-owned enterprise under the Xiamen municipal government, C&D Emerging Investment has always regarded promoting the industrial upgrading of Xiamen and introducing new momentum for regional economic development as an important mission. Going forward, C&D Emerging Investment will continue to work with its partners, leveraging long-term capital and industry resources to deeply empower entrepreneurs, using technology to drive innovation implementation, promote industrial upgrading, and create value, contributing to the realization of high-quality economic development and social progress.